Zeus Hygia Lifesciences in MoU with UK-based Patch House

Develop transdermal delivery systems for premium nutraceutical ingredients

Zeus Hygia Lifesciences, a science-led nutraceutical ingredient innovator, announced the signing of a Memorandum of Understanding (MoU) with UK-based Patch House Labs to jointly develop and commercialise premium nutraceutical
ingredients in advanced transdermal delivery formats. The collaboration marks a strategic step towards expanding the delivery formats of clinically validated nutraceutical ingredients for global consumers.

The partnership will focus on transforming Zeus Hygia’s proprietary branded ingredients into transdermal delivery systems (TDDS), enabling improved bioavailability, convenience, and compliance. Initial ingredients planned for development include Metaberine, a clinically validated low-dose berberine for metabolic health and glucose management; STADICE, an enriched mango extract for cognitive wellness, focus, and memory; and Grantria, a pomegranate extract positioned for beauty-from-within and menopausal health applications.

“We see strong synergies between our science-led ingredient platforms and Patch House Labs’ delivery expertise,” said Dr Arunkanth Krishnakumar, Co-founder and CEO, Zeus Hygia Lifesciences. “This collaboration allows us to extend the reach and efficacy of our clinically validated ingredients through novel delivery formats that enhance consumer experience and therapeutic potential.”

Isaac Davidson, Founder, Patch House Labs, added, “Zeus Hygia’s commitment to research-driven, premium nutraceutical ingredients aligns strongly with our mission to deliver high-performance transdermal solutions. By combining our formulation and testing capabilities with Zeus Hygia’s patented ingredients, we aim to create differentiated transdermal supplements that can penetrate global markets.”